Article ; Online: Sodium-glucose cotransporter 2 inhibitors: are they ready for prime time in the management of lupus nephritis?
Current opinion in rheumatology
2024 Volume 36, Issue 3, Page(s) 163–168
Abstract: Purpose of review: Lupus nephritis is a common complication of systemic lupus erythematosus and is associated with significant morbidity and mortality. The utility of sodium-glucose cotransporter 2 (SGLT2) inhibitors in the management of lupus nephritis ...
Abstract | Purpose of review: Lupus nephritis is a common complication of systemic lupus erythematosus and is associated with significant morbidity and mortality. The utility of sodium-glucose cotransporter 2 (SGLT2) inhibitors in the management of lupus nephritis is currently uncertain. Here, we summarize the rationale for their use among patient with lupus nephritis. Recent findings: SGLT2 inhibitors were initially developed as antihyperglycemic agents. They have since been shown to have additional, profound effects to slow the progression of chronic kidney disease and lessen the long-term risks of cardiovascular disease in large clinic trials of patients with chronic kidney disease, with and without diabetes, as well as in patients with and without proteinuria. Patients with recent exposure to immunosuppression were excluded from these trials due to concern for risk of infection. In the few, small trials of patients with lupus nephritis, SGLT2 inhibitors were found to be well tolerated. They have been shown to reduce proteinuria and to have modest beneficial effects on blood pressure and BMI among patients with lupus nephritis. They have not been shown to influence disease activity. Summary: SGLT2 inhibitors may have a role in mitigating the chronic renal and cardiovascular effects of lupus nephritis. They should be introduced after kidney function has been stabilized with appropriate immunosuppression, in conjunction with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. They currently have no role in active disease. |
---|---|
MeSH term(s) | Humans ; Glucose/metabolism ; Lupus Nephritis/drug therapy ; Lupus Nephritis/complications ; Proteinuria/drug therapy ; Proteinuria/etiology ; Renal Insufficiency, Chronic/complications ; Sodium/metabolism ; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use |
Chemical Substances | Glucose (IY9XDZ35W2) ; Sodium (9NEZ333N27) ; Sodium-Glucose Transporter 2 Inhibitors |
Language | English |
Publishing date | 2024-01-31 |
Publishing country | United States |
Document type | Review ; Journal Article |
ZDB-ID | 1045317-9 |
ISSN | 1531-6963 ; 1040-8711 |
ISSN (online) | 1531-6963 |
ISSN | 1040-8711 |
DOI | 10.1097/BOR.0000000000001002 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 3028: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.